JP2023508097A5 - - Google Patents

Info

Publication number
JP2023508097A5
JP2023508097A5 JP2022539058A JP2022539058A JP2023508097A5 JP 2023508097 A5 JP2023508097 A5 JP 2023508097A5 JP 2022539058 A JP2022539058 A JP 2022539058A JP 2022539058 A JP2022539058 A JP 2022539058A JP 2023508097 A5 JP2023508097 A5 JP 2023508097A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound according
optical isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022539058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508097A (ja
JP7791087B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/138572 external-priority patent/WO2021129653A1/zh
Publication of JP2023508097A publication Critical patent/JP2023508097A/ja
Publication of JP2023508097A5 publication Critical patent/JP2023508097A5/ja
Application granted granted Critical
Publication of JP7791087B2 publication Critical patent/JP7791087B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022539058A 2019-12-23 2020-12-23 タンパク質分解剤化合物の製造方法及び使用 Active JP7791087B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201911342649 2019-12-23
CN201911342649.0 2019-12-23
CN202010200682 2020-03-20
CN202010200682.6 2020-03-20
CN202010496353.0 2020-06-03
CN202010496353 2020-06-03
CN202011486334 2020-12-16
CN202011486334.6 2020-12-16
PCT/CN2020/138572 WO2021129653A1 (zh) 2019-12-23 2020-12-23 一种蛋白降解剂化合物的制备方法和应用

Publications (3)

Publication Number Publication Date
JP2023508097A JP2023508097A (ja) 2023-02-28
JP2023508097A5 true JP2023508097A5 (enExample) 2024-01-09
JP7791087B2 JP7791087B2 (ja) 2025-12-23

Family

ID=76573691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539058A Active JP7791087B2 (ja) 2019-12-23 2020-12-23 タンパク質分解剤化合物の製造方法及び使用

Country Status (19)

Country Link
US (2) US12441706B2 (enExample)
EP (1) EP4083020A4 (enExample)
JP (1) JP7791087B2 (enExample)
KR (1) KR20220120629A (enExample)
CN (2) CN114829342A (enExample)
AU (1) AU2020414151A1 (enExample)
BR (1) BR112022012385A2 (enExample)
CA (1) CA3162523A1 (enExample)
CL (1) CL2022001724A1 (enExample)
CO (1) CO2022010305A2 (enExample)
EC (1) ECSP22056811A (enExample)
IL (1) IL294225B1 (enExample)
JO (1) JOP20220159A1 (enExample)
MX (1) MX2022007885A (enExample)
PE (1) PE20230114A1 (enExample)
PH (1) PH12022551571A1 (enExample)
TW (1) TWI755992B (enExample)
WO (1) WO2021129653A1 (enExample)
ZA (1) ZA202208051B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
CR20230007A (es) 2020-06-12 2023-06-01 Shanghai Jemincare Pharmaceuticals Co Ltd Compuesto de ftalazinona, y método de preparación y uso médico de este.
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
IL301690A (en) * 2020-10-16 2023-05-01 Dana Farber Cancer Inst Inc Piperidinyl small molecule degraders of helios and methods of use
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
CA3226162A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
AU2023300784A1 (en) * 2022-06-30 2025-01-02 Anhorn Medicines Co., Ltd. Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related diseases by using the same
WO2024012570A1 (zh) * 2022-07-15 2024-01-18 西藏海思科制药有限公司 一种含氮杂环衍生物及其组合物和药学上的应用
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245804B1 (en) 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
RU2738833C9 (ru) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
CN107709290B (zh) 2015-04-21 2023-02-28 Gtx公司 选择性雄激素受体降解剂(sard)配体和其使用方法
CA2988414C (en) 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
CA3042297A1 (en) * 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
WO2018098280A1 (en) * 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
CN110194762B (zh) 2018-02-27 2021-09-10 中国科学院上海药物研究所 酞嗪酮类衍生物、其制备方法和用途
CN112390852B (zh) 2019-08-14 2022-10-18 上海济煜医药科技有限公司 作为蛋白降解剂的化合物及其制备方法和应用
CN112457366B (zh) 2019-09-06 2024-03-19 江西济民可信集团有限公司 作为蛋白降解剂的并环类化合物及其制备方法和应用
CN112457367B (zh) 2019-09-06 2022-08-23 上海济煜医药科技有限公司 作为蛋白降解剂的连环类化合物及其制备方法和应用
CN118930604A (zh) 2019-09-29 2024-11-12 江西济民可信集团有限公司 作为蛋白降解剂杂环类化合物及包含其的药物组合物和应用
CN113582974B (zh) 2020-04-30 2022-05-17 江西济民可信集团有限公司 一类作为蛋白降解剂的化合物及其制备方法和医药用途
CR20230007A (es) 2020-06-12 2023-06-01 Shanghai Jemincare Pharmaceuticals Co Ltd Compuesto de ftalazinona, y método de preparación y uso médico de este.

Similar Documents

Publication Publication Date Title
JP2023508097A5 (enExample)
JP2023531390A5 (enExample)
RU2006112428A (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2011509309A5 (enExample)
RU2009103810A (ru) Новые соединения
JP2022023958A5 (enExample)
RU2006112427A (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
JP2007507494A5 (enExample)
RU2018106453A (ru) Соединения
JP2016518437A5 (enExample)
RU2010136050A (ru) 2-аминохинолиновые производные для использования в качестве ингибиторов секретазы (васе)
JP2023531517A5 (enExample)
JP2012522759A5 (enExample)
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
JP2022529371A5 (enExample)
RU2007147344A (ru) Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний
CN110225781A (zh) 噻唑衍生物及其应用
JP2019529460A5 (enExample)
JP2021521178A5 (enExample)
JP2023522725A5 (enExample)
JP2023067881A5 (enExample)
JP2022529309A5 (enExample)
RU2009128970A (ru) Производные изосорбидмононитрата для лечения кишечных заболеваний
JP2012505905A5 (enExample)